Essel Dulaimi

4.0k total citations
56 papers, 2.5k citations indexed

About

Essel Dulaimi is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Essel Dulaimi has authored 56 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 20 papers in Pulmonary and Respiratory Medicine and 15 papers in Oncology. Recurrent topics in Essel Dulaimi's work include Renal cell carcinoma treatment (20 papers), Renal and related cancers (16 papers) and Epigenetics and DNA Methylation (14 papers). Essel Dulaimi is often cited by papers focused on Renal cell carcinoma treatment (20 papers), Renal and related cancers (16 papers) and Epigenetics and DNA Methylation (14 papers). Essel Dulaimi collaborates with scholars based in United States, Russia and United Kingdom. Essel Dulaimi's co-authors include Tahseen Al‐Saleem, Robert G. Uzzo, Paul Cairns, Inmaculada Ibañez de Cáceres, Richard E. Greenberg, Elizabeth R. Plimack, Joseph R. Testa, Gary R. Hudes, Alexander W. Macfarlane and Kerry S. Campbell and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Essel Dulaimi

56 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Essel Dulaimi United States 25 1.4k 682 651 536 517 56 2.5k
Kolja Freier Germany 30 894 0.6× 440 0.6× 903 1.4× 381 0.7× 835 1.6× 99 2.6k
Benedicte Parm Ulhøi Denmark 27 856 0.6× 445 0.7× 511 0.8× 567 1.1× 800 1.5× 66 2.1k
Philipp Erben Germany 32 830 0.6× 468 0.7× 640 1.0× 355 0.7× 699 1.4× 161 3.8k
Kanako C. Hatanaka Japan 24 564 0.4× 409 0.6× 613 0.9× 400 0.7× 486 0.9× 143 2.0k
H. Ewout Schaafsma Netherlands 20 1.3k 0.9× 707 1.0× 483 0.7× 286 0.5× 517 1.0× 40 2.4k
Kurt R. Weiss United States 23 770 0.5× 445 0.7× 431 0.7× 323 0.6× 306 0.6× 79 1.8k
Ofer Ben‐Izhak Israel 30 1.1k 0.8× 492 0.7× 1.3k 2.0× 358 0.7× 497 1.0× 100 2.7k
Antonio Cavaliere Italy 22 728 0.5× 349 0.5× 726 1.1× 378 0.7× 348 0.7× 72 2.3k
Edwin C. Douglass United States 31 1.5k 1.0× 1.1k 1.6× 826 1.3× 368 0.7× 518 1.0× 70 3.3k
Marta Salido Spain 27 709 0.5× 758 1.1× 1.3k 2.0× 683 1.3× 249 0.5× 111 2.5k

Countries citing papers authored by Essel Dulaimi

Since Specialization
Citations

This map shows the geographic impact of Essel Dulaimi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Essel Dulaimi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Essel Dulaimi more than expected).

Fields of papers citing papers by Essel Dulaimi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Essel Dulaimi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Essel Dulaimi. The network helps show where Essel Dulaimi may publish in the future.

Co-authorship network of co-authors of Essel Dulaimi

This figure shows the co-authorship network connecting the top 25 collaborators of Essel Dulaimi. A scholar is included among the top collaborators of Essel Dulaimi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Essel Dulaimi. Essel Dulaimi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Macfarlane, Alexander W., R. Katherine Alpaugh, Essel Dulaimi, et al.. (2021). Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms. Cancer Immunology Immunotherapy. 70(7). 1893–1906. 8 indexed citations
2.
D’Agati, Vivette D., et al.. (2021). Light chain cast nephropathy caused by plasmablastic lymphoma of the bladder. PubMed. 9(1). 72–80. 4 indexed citations
3.
Cai, Weijia, Liya Su, Lili Liao, et al.. (2019). PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. Nature Communications. 10(1). 5800–5800. 55 indexed citations
4.
Nejati, Reza, Shuanzeng Wei, Robert G. Uzzo, et al.. (2019). Monosomy of Chromosome 9 Is Associated With Higher Grade, Advanced Stage, and Adverse Outcome in Clear-cell Renal Cell Carcinoma. Clinical Genitourinary Cancer. 18(1). 56–61. 4 indexed citations
5.
Pei, Jianming, Harry S. Cooper, Douglas B. Flieder, et al.. (2019). NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma. Modern Pathology. 32(5). 710–716. 59 indexed citations
6.
Barta, Stefan K., Jasmine Zain, Alexander W. Macfarlane, et al.. (2019). Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 19(6). 356–364.e3. 90 indexed citations
7.
Ghatalia, Pooja, Jennifer Gordetsky, Fengshen Kuo, et al.. (2019). Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 7(1). 139–139. 120 indexed citations
8.
Franco‐Barraza, Janusz, Ralph Francescone, Neelima Shah, et al.. (2017). Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence. eLife. 6. 78 indexed citations
9.
Jiang, Wei, Essel Dulaimi, Karthik Devarajan, et al.. (2016). Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma. PLoS ONE. 11(10). e0164554–e0164554. 20 indexed citations
10.
Plimack, Elizabeth R., Roland L. Dunbrack, Timothy Brennan, et al.. (2015). Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer.. Journal of Clinical Oncology. 33(7_suppl). 320–320. 9 indexed citations
11.
Dulaimi, Essel, et al.. (2014). A global profile of gene promoter methylation in treatment-naïve urothelial cancer. Epigenetics. 9(5). 760–773. 30 indexed citations
12.
13.
Macfarlane, Alexander W., Elizabeth R. Plimack, Gary R. Hudes, et al.. (2013). PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection. Cancer Immunology Research. 2(4). 320–331. 141 indexed citations
14.
Wu, Andrew S., Sameer Kalghatgi, Danil Dobrynin, et al.. (2012). Porcine intact and wounded skin responses to atmospheric nonthermal plasma. Journal of Surgical Research. 179(1). e1–e12. 68 indexed citations
15.
Cáceres, Inmaculada Ibañez de, Anna Potapova, Essel Dulaimi, et al.. (2010). Global Reactivation of Epigenetically Silenced Genes in Prostate Cancer. Cancer Prevention Research. 3(9). 1084–1092. 35 indexed citations
16.
Cáceres, Inmaculada Ibañez de, et al.. (2006). Identification of Novel Target Genes by an Epigenetic Reactivation Screen of Renal Cancer. Cancer Research. 66(10). 5021–5028. 133 indexed citations
17.
Al‐Saleem, Tahseen, Paul Cairns, Essel Dulaimi, et al.. (2004). The genetics of renal oncocytosis: a possible modelfor neoplastic progression. Cancer Genetics and Cytogenetics. 152(1). 23–28. 40 indexed citations
18.
Dulaimi, Essel, Robert G. Uzzo, Richard E. Greenberg, Tahseen Al‐Saleem, & Paul Cairns. (2004). Detection of Bladder Cancer in Urine by a Tumor Suppressor Gene Hypermethylation Panel. Clinical Cancer Research. 10(6). 1887–1893. 154 indexed citations
19.
Sauter, Edward R., et al.. (2004). Detection of Breast Cancer in Nipple Aspirate Fluid by CpG Island Hypermethylation. Clinical Cancer Research. 10(1). 28–32. 127 indexed citations
20.
Dulaimi, Essel, et al.. (2004). Tumor Suppressor Gene Promoter Hypermethylation in Serum of Breast Cancer Patients. Clinical Cancer Research. 10(18). 6189–6193. 183 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kolja Freier Breakdown of academic impact, for papers by Benedicte Parm Ulhøi Breakdown of academic impact, for papers by Philipp Erben Breakdown of academic impact, for papers by Kanako C. Hatanaka Breakdown of academic impact, for papers by H. Ewout Schaafsma Breakdown of academic impact, for papers by Kurt R. Weiss Breakdown of academic impact, for papers by Ofer Ben‐Izhak Breakdown of academic impact, for papers by Antonio Cavaliere Breakdown of academic impact, for papers by Edwin C. Douglass Breakdown of academic impact, for papers by Marta Salido
Rankless by CCL
2026